Literature DB >> 15621835

Role of the STAT1 pathway in apoptosis induced by fludarabine and JAK kinase inhibitors in B-cell chronic lymphocytic leukemia.

Luis Martinez-Lostao1, Javier Briones, Ignasi Forné, Monica Martinez-Gallo, Beatriz Ferrer, Jordi Sierra, Jose Luis Rodriguez-Sanchez, Candido Juarez.   

Abstract

Signal transducers and activators of transcription (STAT) proteins comprise a family of transcription factors that have been implicated in tumoral transformation, especially in hematological malignancies. Because of this, the JAK/STAT pathway is attractive as a therapeutic target in these tumors. In the present study, we analyzed the ability of fludarabine and two JAK kinase inhibitors, AG490 and WHI-P131, to block STAT1 activation and induce apoptosis on B-cell chronic lymphocytic leukemia (B-CLL) cells. All drugs were able to induce a high percentage of apoptosis on B-CLL cells from all patients studied. However, only AG490 and WHI-P131 were able to strongly suppress the STAT1 activation of B-CLL cells. In conclusion, our data show that JAK kinase inhibitors, such as AG490 and WHI-P131 are able to inhibit the STAT1 pathway on B-CLL cells and are strong inductors of apoptosis on these cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15621835     DOI: 10.1080/10428190400018398

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  9 in total

1.  Differential regulation of umbilical cord blood and leukemic B cells by interferon-alpha (IFN-alpha): observations in cultured cells.

Authors:  István Szegedi; Csongor Kiss; Eva Karászi; György Vámosi; János Szöllôsi; Péter Kovács; Ilona Benkô
Journal:  Pathol Oncol Res       Date:  2006-09-23       Impact factor: 3.201

2.  In silico investigations identified Butyl Xanalterate to competently target CK2α (CSNK2A1) for therapy of chronic lymphocytic leukemia.

Authors:  Suliman A Alsagaby; Danish Iqbal; Iqrar Ahmad; Harun Patel; Shabir Ahmad Mir; Yahya Awaji Madkhali; Atif Abdulwahab A Oyouni; Yousef M Hawsawi; Fahad A Alhumaydhi; Bader Alshehri; Wael Alturaiki; Bader Alanazi; Manzoor Ahmad Mir; Waleed Al Abdulmonem
Journal:  Sci Rep       Date:  2022-10-21       Impact factor: 4.996

3.  The effects of fludarabine on rat cerebral ischemia.

Authors:  Qian Xu; Chunjuan Jiang; Yutao Rong; Chun Yang; Ying Liu; Kai Xu
Journal:  J Mol Neurosci       Date:  2014-05-15       Impact factor: 3.444

Review 4.  Targeting inflammatory pathways in chronic lymphocytic leukemia.

Authors:  Uri Rozovski; Michael J Keating; Zeev Estrov
Journal:  Crit Rev Oncol Hematol       Date:  2013-08-12       Impact factor: 6.312

5.  JAK inhibitors AG-490 and WHI-P154 decrease IFN-gamma-induced iNOS expression and NO production in macrophages.

Authors:  Outi Sareila; Riku Korhonen; Outi Kärpänniemi; Riina Nieminen; Hannu Kankaanranta; Eeva Moilanen
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

6.  Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma.

Authors:  Irene Dell'Anno; Sarah A Martin; Marcella Barbarino; Alessandra Melani; Roberto Silvestri; Maria Bottaro; Elisa Paolicchi; Alda Corrado; Monica Cipollini; Ombretta Melaiu; Antonio Giordano; Luca Luzzi; Federica Gemignani; Stefano Landi
Journal:  Invest New Drugs       Date:  2020-12-09       Impact factor: 3.850

7.  Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles.

Authors:  L Rickardson; M Fryknäs; S Dhar; H Lövborg; J Gullbo; M Rydåker; P Nygren; M G Gustafsson; R Larsson; A Isaksson
Journal:  Br J Cancer       Date:  2005-08-22       Impact factor: 7.640

8.  Role of CTLA4 in the proliferation and survival of chronic lymphocytic leukemia.

Authors:  Amit K Mittal; Nagendra K Chaturvedi; Rae A Rohlfsen; Payal Gupta; Avadhut D Joshi; Ganapati V Hegde; R Gregory Bociek; Shantaram S Joshi
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

9.  Prognostic significance of signal transducer and activator of transcription 5 and 5b expression in Epstein-Barr virus-positive patients with chronic lymphocytic leukemia.

Authors:  Panagiotis T Diamantopoulos; Maria Sofotasiou; Zafiroula Georgoussi; Nefeli Giannakopoulou; Vasiliki Papadopoulou; Athanasios Galanopoulos; Elina Kontandreopoulou; Panagiotis Zervakis; Paschalina Pallaki; Fani Kalala; Marie-Christine Kyrtsonis; Aglaia Dimitrakopoulou; Theodoros Vassilakopoulos; Maria Angelopoulou; Nikolaos Spanakis; Nora-Athina Viniou
Journal:  Cancer Med       Date:  2016-07-01       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.